InvestSMART

Ceryvyn Therapeutics Limited (ASX: CYV) - Financials

Current share price for CYV : $0.011 0 (4.55%)+

Ceryvyn Therapeutics Limited (CYV, formerly Opthea Limited) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is an ASX listed biopharmaceutical company which researches and develops novel therapeutic products based on targeting Vascular Endothelial Growth Factors (VEGF) C, D and R3. Since FY2014, the Company has been committed to the development of new therapies for the treatment of serious eye diseases that affect the back of the eye, or retina, and lead to vision loss. The Company's lead candidate was sozinibercept a VEGF C/D trap inhibitor being developed for use in conjunction with VEGF A inhibitors for the treatment of wet AMD and other retinal diseases.

CYV Per Share

Year to Jun Sales Cashflow Earnings Dividends Franking Book Value Average
Annual P/E		 Relative P/E Shareholder Return
2026 -0.9 ¢ -2 ¢ 0 ¢ 0% $0.02 0 0% -97.5%
2025 -19.8 ¢ -20.3 ¢ 0 ¢ 0% -$0.25 0 0% 71.4%
2024 -38.1 ¢ -52.1 ¢ 0 ¢ 0% -$0.10 0 0% -26.7%

CYV Capital Structure

Total Debt Interest Long Term Debt Percent Debt Preferred Stock Share Equity Percent Equity
$0.00 $11,059 $0.00 0% $0.00 $29,615 100%
Note: All dollars in thousands ('000) for the table above

CYV Historical Financials

2026 2025 2024
Revenue ($M) 0.2
Operating Margin (%) -1,689,100 -514,688 -162,580.8
Depreciation ($M) -0.1 -0.2
Amortisation ($M)
Net Profit Before Abs ($M) -26.7 -248.5 -332.5
Net Profit After Abs ($M) 330.4 -248.5 -332.5
Income Tax Rate (%) -0.1 4.1 4.1
Net Profit Margin (%) -2,669,700 -650,964 -176,665.7
Employees ($T)
Long Term Debt ($M) 302.7
Shareholders Equity ($M) 29.6 -307 -114.4
Return on Capital (%) -64 -160
Return on Equity (%) -90.1
Payout Ratio (%)

CYV Cashflow

2026 2025 2024
Customer Receipts ($M)
Net Operating Cashflow ($M) -12.5 -242.2 -243.1
Net Investing Cashflow ($M)
Net Financing Cashflow ($M) -31 53 368

CYV Market & Earnings

2026 2025 2024
Market Cap ($M) 21 739 382
Net Gearing (%) -101.4 -98.8 -37.1
Net Interest Cover (%) -1.69 -3.15 -7.55
Dividend Yield (%)
NTA Per Share ($) 0.02 -0.25 -0.1
EBITDA ($M) -16.9 -196.4 -306
EBIT ($M) -16.9 -196.6 -306.1
EBT Before Abs ($M) -26.9 -259.1 -346.7

CYV Balance Sheet

2026 2025 2024
Cash ($M) 30 74 260.4
Debtors ($M)
Other Debtors ($M) 0.4 0.64 2.15
Prepayments ($M) 0.81 1.15 5.88
Inventories ($M)
Current Investments ($M)
Other Current Assets ($M) 0.7 10.97 15.7
Total Current Assets ($M) 31.9 86.7 284.1
Receivables ($M)
Inventories ($M)
Property, Plant & Equipment ($M) 0.88
Accumulated Depreciation ($M) -0.68
Intangibles ex. Goodwill ($M)
Goodwill ($M)
Future Income Tax Benefit ($M)
Non-Current Investments ($M)
Other Non-Current Assets ($M) 0.7
Total Non-Current Assets ($M) 0.9
Total Assets ($M) 31.9 86.7 285
Accounts Payable ($M) 2.32 14.86 57.52
Provisions ($M) 1.74 39.04
Short Term Debt ($M) 377.09 0.14
Other Current Liabilities ($M)
Total Current Liabilities ($M) 2.32 393.69 96.7
Creditors ($M)
Long Term Debt ($M) 302.7
Provisions ($M) 0.01
Other Non-Current Liabilities ($M)
Total Non-Current Liabilities ($M) 302.8
Total Liabilities ($M) 2.32 393.69 399.46
Share Capital ($M) 732.5 759.5 703.6
Reserves ex. Share Premium ($M) 56.8 67.1 57.1
Share Premium Reserve ($M)
Retained Profits ($M) -759.6 -1,133.6 -875.2
Other Shareholders Equity ($M)
Convertible Equity ($M)
Outside Equity Interest ($M)
Total Shareholders Equity ($M) 29.6 -307 -114.4

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.